

## DAFTAR PUSTAKA

- Aitbekov, R., Murzakhmetova, M., Zhamanbayeva, G., Zhaparkulova, N., Seel, H. (2022). Epidemiological Features of Acute Myeloid Leukemia in Five Regions of the Republic of Kazakhstan: Population Study. *Asian Pacific Journal of Cancer Prevention*, 23(12), pp.4163–4167. doi:<https://doi.org/10.31557/apjcp.2022.23.12.4163>.
- Al-Ghazaly, J. (2014). A Ten Year Descriptive Study of Adult Leukaemia at Al-Jomhori Teaching Hospital in Sana'a, Yemen. *Article in Yemeni Journal For Medical Sciences*. doi:<https://doi.org/10.20428/YJMS.8.1.1>.
- Allegra, A., Caserta, S., Mirabile, G. and Gangemi, S. (2023). Aging and Age-Related Epigenetic Drift in the Pathogenesis of Leukemia and Lymphomas: New Therapeutic Targets. *Cells*, [online] 12(19), p.2392. doi:<https://doi.org/10.3390/cells12192392>.
- Angelini, M., Teglia, F., Astolfi, L., Casolari, G., Boffetta, P. (2023). Decrease of cancer diagnosis during COVID-19 pandemic: a systematic review and meta-analysis. *European Journal of Epidemiology*, 38(1), pp.31–38. doi:<https://doi.org/10.1007/s10654-022-00946-6>.
- Arber, D.A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M.J., Le Beau, M.M., Bloomfield, C.D., Cazzola, M., Vardiman, J.W. (2016). The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood*, [online] 127(20), pp.2391–2405. doi:<https://doi.org/10.1182/blood-2016-03-643544>.
- Aster, J. dan Stone, R. (2022). *Clinical manifestations and diagnosis of myelodysplastic syndromes (MDS)*. [online] Uptodate.com. Available at:

<https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-myelodysplastic-syndromes-mds> [Accessed 6 Dec. 2022].

Barbui, T., Thiele, J., Gisslinger, H., Kvasnicka, H.M., Vannucchi, A.M., Guglielmelli, P., Orazi, A., Tefferi, A. (2018). The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. *Blood Cancer Journal*, [online] 8(2). doi:<https://doi.org/10.1038/s41408-018-0054-y>.

Bassig, B.A., Hu, W., Morton, L.M., Ji, B., Xu, J., Linet, M.S., Kwong, Y., Rothman, N., Wong, K., Lan, Q. (2022). Incidence of myeloid malignancies by subtype in Hong Kong and comparisons with Asian and white men and women in the United States. *Leukemia & Lymphoma*, 63(8), pp.1917–1924. doi:<https://doi.org/10.1080/10428194.2022.2045593>.

Behrmann, L., Wellbrock, J., Fiedler, W. (2020). The bone marrow stromal niche: a therapeutic target of hematological myeloid malignancies. *Expert Opinion on Therapeutic Targets*, 24(5), pp.451–462. doi:<https://doi.org/10.1080/14728222.2020.1744850>.

Belai, N., Ghebrenigus, A.S., Alamin, A.A., Embaye, G., Andegiorgish, A.K. (2019). Patterns of bone marrow aspiration confirmed hematological malignancies in Eritrean National Health Laboratory. *BMC Hematology*, [online] 19(1). doi:<https://doi.org/10.1186/s12878-019-0138-3>.

Bunn, H.F. dan Aster, J.C. (2011). *Pathophysiology of blood disorders*. New York, N.Y.: McGraw-Hill Education Llc., C.

canreg.fkkmk (2022). *RKBR Maret 2022*. [online] [ugm.ac.id](http://ugm.ac.id). Available at: <https://canreg.fk.ugm.ac.id/laporan-data/registrasi-kanker-berbasis-rumah-sakit-dr-sardjito-fkkmk-ugm/rkbr-maret-2022/> [Accessed 21 Dec. 2022].

- Cashen, A. dan Van Tine, B. (2012). *The Washington manual hematology and oncology subspecialty consult*. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins.
- Chauffaille, M.L.L.F., Figueiredo, M.S., Beltrani, R., Antunes, S.V., Yamamoto, M., Kerbauy, J. (2001). Acute promyelocytic leukemia: the study of t(15;17) translocation by fluorescent in situ hybridization, reverse transcriptase-polymerase chain reaction and cytogenetic techniques. *Brazilian Journal of Medical and Biological Research*, 34(6), pp.735–743. doi:<https://doi.org/10.1590/s0100-879x2001000600006>.
- Chihara, D., Ito, H., Matsuda, T., Shibata, A., Katsumi, A., Nakamura, S., Tomotaka, S., Morton, L.M., Weisenburger, D.D., Matsuo, K. (2013). Differences in incidence and trends of haematological malignancies in Japan and the United States. *British Journal of Haematology*, 164(4), pp.536–545. doi:<https://doi.org/10.1111/bjh.12659>.
- Clara, J., Sallman, D., Padron, E. (2016). Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes. *Cancer Biology & Medicine*, [online] 13(3), pp.360–372. doi:<https://doi.org/10.20892/j.issn.2095-3941.2016.0043>.
- Cogle, C.R. (2015). Incidence and Burden of the Myelodysplastic Syndromes. *Current Hematologic Malignancy Reports*, 10(3), pp.272–281. doi:<https://doi.org/10.1007/s11899-015-0269-y>.
- Craig, B.M., Rollison, D.E., List, A.F., Cogle, C.R. (2012). Underreporting of Myeloid Malignancies by United States Cancer Registries. *Cancer Epidemiology Biomarkers & Prevention*, 21(3), pp.474–481. doi:<https://doi.org/10.1158/1055-9965.epi-11-1087>.

- Cui, X., Zhao, X. and Liang, Y. (2022). Sex differences in normal and malignant hematopoiesis. *Blood Science*, [online] 4(4), pp.185–191. doi:<https://doi.org/10.1097/BS9.0000000000000133>.
- Decker, K., Feely, A., Bucher, O., Czaykowski, P., Hebbard, P., Kim, J.O., Pitz, M., Singh, H., Thiessen, M., Lambert, P. (2023). New Cancer Diagnoses Before and During the COVID-19 Pandemic. *JAMA network open*, 6(9), pp.e2332363–e2332363. doi:<https://doi.org/10.1001/jamanetworkopen.2023.32363>.
- Deschler, B. dan Lübbert, M. (2006). Acute myeloid leukemia: Epidemiology and etiology. *Cancer*, 107(9), pp.2099–2107. doi:<https://doi.org/10.1002/cncr.22233>.
- Dinmohamed, A.G., van Norden, Y., Visser, O., Posthuma, E.F.M., Huijgens, P.C., Sonneveld, P., van de Loosdrecht, A.A., Jongen-Lavrencic, M. (2015). The use of medical claims to assess incidence, diagnostic procedures and initial treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia in the Netherlands. *Leukemia Research*, 39(2), pp.177–182. doi:<https://doi.org/10.1016/j.leukres.2014.11.025>.
- Dong, Y., Shi, O., Zeng, Q., Lu, X., Wang, W., Li, Y., Wang, Q. (2020). Leukemia incidence trends at the global, regional, and national level between 1990 and 2017. *Experimental Hematology & Oncology*, 9(1). doi:<https://doi.org/10.1186/s40164-020-00170-6>.
- Drescher, C.W., Bograd, A.J., Chang, S., Weerasinghe, R.K., Vita, A., Bell, R.B. (2021). Cancer case trends following the onset of the COVID-19 pandemic: A community-based observational study with extended follow-up. *Cancer*. doi:<https://doi.org/10.1002/cncr.34067>.
- Enawgaw, B., Aynalem, M., Melku, M., Asrie, F., Abebe, M., Yalew, A., Bekele, T., Mesfin, N., Ayalew, M., Shiferaw, E. (2021). Hematological malignancies in the

Northwest Ethiopia. *PLOS ONE*, [online] 16(12), p.e0260639. doi:<https://doi.org/10.1371/journal.pone.0260639>.

Fitzmaurice, C., Allen, C., Barber, R.M., Barregard, L., Bhutta, Z.A., Brenner, H., Dicker, D.J., Chimed-Orchir, O., Dandona, R., Dandona, L., Fleming, T., Forouzanfar, M.H., Hancock, J., Hay, R.J., Hunter-Merrill, R., Huynh, C., Hosgood, H.D., Johnson, C.O., Jonas, J.B., Khubchandani, J. (2017). Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. *JAMA Oncology*, 3(4), pp.524–548. doi:<https://doi.org/10.1001/jamaoncol.2016.5688>.

Fowlkes, S., Murray, C., Fulford, A., De Gelder, T., Siddiq, N. (2018). Myeloproliferative neoplasms (MPNs) – Part 1: An overview of the diagnosis and treatment of the ‘classical’ MPNs. *Canadian Oncology Nursing Journal*, [online] 28(4), pp.262–268. doi:<https://doi.org/10.5737/23688076284262268>.

Freedman, A., Friedberg, J., Aster, J., Gurbuxani, S., Sekeres, M. (2022). *Classification of hematopoietic neoplasms*. [online] Uptodate.com. Available at: <https://www.uptodate.com/contents/classification-of-hematopoietic-neoplasms> [Accessed 18 Dec. 2022].

George, B., Yohannan, B., Gonzalez, A., Rios, A. (2022). Mixed-Phenotype Acute Leukemia: Clinical Diagnosis and Therapeutic Strategies. *Biomedicines*, [online] 10(8), pp.1974–1974. doi:<https://doi.org/10.3390/biomedicines10081974>.

Haferlach, T., Kohlmann, A., Schnittger, S., Dugas, M., Hiddemann, W., Kern, W., Schoch, C. (2005). AML M3 and AML M3 variant each have a distinct gene expression signature but also share patterns different from other genetically

defined AML subtypes. *Genes, Chromosomes and Cancer*, [online] 43(2), pp.113–127. doi:<https://doi.org/10.1002/gcc.20175>.

Heel, K., Tabone, T., Röhrig, K.J., Maslen, P.G., Meehan, K., Grimwade, L.F., Erber, W.N. (2013). Developments in the immunophenotypic analysis of haematological malignancies. *Blood Reviews*, 27(4), pp.193–207. doi:<https://doi.org/10.1016/j.blre.2013.06.005>.

Heer, E., Ruan, Y., Boyne, D.J., Jarada, T.N., Heng, D., Henning, J.-W., Morris, D.M., O’Sullivan, D.E., Cheung, W.Y., Brenner, D.R. (2023). Impact of the COVID-19 pandemic on cancer diagnoses, stage and survival in Alberta. *CMAJ*, [online] 195(23), pp.E804–E812. doi:<https://doi.org/10.1503/cmaj.221512>.

Herzog, C.M., Dey, S., Hablas, A., Khaled, H.M., Seifeldin, I.A., Ramadan, M., El-Hamzawy, H., Wilson, M.L., Soliman, A.S. (2012). Geographic distribution of hematopoietic cancers in the Nile delta of Egypt. *Annals of Oncology*, [online] 23(10), pp.2748–2755. doi:<https://doi.org/10.1093/annonc/mds079>.

Hong, M. dan He, G. (2017). The 2016 revision to the World Health Organization classification of myelodysplastic syndromes. *Journal of Translational Internal Medicine*, [online] 5(3), pp.139–143. doi:<https://doi.org/10.1515/jtim-2017-0002>.

Hu, Y., Li, Q., Hou, M., Peng, J., Yang, X., Xu, S. (2021). Magnitude and Temporal Trend of the Chronic Myeloid Leukemia: On the Basis of the Global Burden of Disease Study 2019. *JCO Global Oncology*, (7), pp.1429–1441. doi:<https://doi.org/10.1200/go.21.00194>.

Huang, H.-H., Chen, C.-M., Wang, C.-Y., Hsu, W.W.-Y., Chen, H.-M., Ko, B.-S., Hsiao, F.-Y. (2022). The epidemiology, treatment patterns, healthcare utilizations

and costs of Acute Myeloid Leukaemia (AML) in Taiwan. *PLOS ONE*, 17(1), p.e0261871. doi:<https://doi.org/10.1371/journal.pone.0261871>.

International Agency for Research on Cancer (2020). Cancer Registries, The Core of Cancer Control. *Global Initiative for Cancer Registry Development*. Available at: [https://gicr.iarc.fr/about-the-gicr/the-value-of-cancer-data/Brochure\\_HD.pdf](https://gicr.iarc.fr/about-the-gicr/the-value-of-cancer-data/Brochure_HD.pdf) [Accessed 25 Oct. 2022].

Ismaeel, A., Farid, E., Majed, K.S., Mansoor, E.J., Toorani, J., Tufail, F., Aldanasoury, R.A., Alsuwaidi, S.A., Shome, D.K. (2022). Hematologic malignancies of primary bone marrow involvement: a decade's experience in Bahrain. *Hematology, Transfusion and Cell Therapy*. doi:<https://doi.org/10.1016/j.htct.2022.02.002>.

Jameson, J. (2018). *Harrison's principles of internal medicine*. 20th ed. New York McGraw-Hill Education.

Khan, A.M. (2012). Why Are Myelodysplastic Syndromes Unrecognized and Underdiagnosed?: A Primary Care Perspective. *The American Journal of Medicine*, 125(7), pp.S15–S17. doi:<https://doi.org/10.1016/j.amjmed.2012.04.017>.

Khoury, J.D., Solary, E., Abla, O., Akkari, Y., Alaggio, R., Apperley, J.F., Bejar, R., Berti, E., Busque, L., Chan, J.K.C., Chen, W., Chen, X., Chng, W.-J., Choi, J.K., Colmenero, I., Coupland, S.E., Cross, N.C.P., De Jong, D., Elghetany, M.T., Takahashi, E. (2022). The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. *Leukemia*, [online] 36(7), pp.1703–1719. doi:<https://doi.org/10.1038/s41375-022-01613-1>.

- Kuendgen, A., Kasprzak, A. dan Germing, U. (2021). Hybrid or Mixed Myelodysplastic/Myeloproliferative Disorders – Epidemiological Features and Overview. *Frontiers in Oncology*, 11. doi:<https://doi.org/10.3389/fonc.2021.778741>.
- Kurniawan, A. (2021). *Pelaksanaan PPKM dalam Penanganan Kasus COVID-19 dan Evaluasinya*. [online] Kemenkeu.go.id. Available at: <https://www.djkn.kemenkeu.go.id/kpknk-semarang/baca-artikel/14314/Pelaksanaan-PPKM-dalam-Penanganan-Kasus-COVID-19-dan-Evaluasinya.html> [Accessed 14 Nov. 2023].
- Larson, R. (2022). *Induction therapy for acute myeloid leukemia in medically-fit adults*. [online] Uptodate.com. Available at: <https://www.uptodate.com/contents/induction-therapy-for-acute-myeloid-leukemia-in-medically-fit-adults> [Accessed 4 Dec. 2022].
- Li, W. (2022). *Leukemia*. Brisbane, Australia: Exon Publications. doi:<https://doi.org/10.36255/exon-publications-leukemia>.
- Lichtman, M.A., Kaushansky, K., Prchal, J.T., Levi, M.M., Burns, L.J., Linch, D.C. (2022). *Williams Manual of Hematology, Tenth Edition*. McGraw Hill Professional.
- Lobato, F. (2017). *M3/M3v acute myeloid leukemia (AML M3/M3v) Acute promyelocytic leukemia (APL) Acute promyelocytic leukemia (APL) PML/RARA*. [online] Atlasgeneticsoncology.org. Available at: [https://atlasgeneticsoncology.org/haematological/1240/m3-m3v-acute-myeloid-leukemia-\(aml-m3-m3v\)-br-acute-promyelocytic-leukemia-\(apl\)-br-acute-promyelocytic-leukemia-\(apl\)-pml-rara](https://atlasgeneticsoncology.org/haematological/1240/m3-m3v-acute-myeloid-leukemia-(aml-m3-m3v)-br-acute-promyelocytic-leukemia-(apl)-br-acute-promyelocytic-leukemia-(apl)-pml-rara) [Accessed 6 Nov. 2023].



Lu, X. dan Chang, R. (2022). *Polycythemia Vera*. [online] Nih.gov. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK557660/> [Accessed 4 Dec. 2022].

Marchand, T. dan Pinho, S. (2021). Leukemic Stem Cells: From Leukemic Niche Biology to Treatment Opportunities. *Frontiers in Immunology*, [online] 12. doi:<https://doi.org/10.3389/fimmu.2021.775128>.

Maynadie, M., Girodon, F., Manivet-Janoray, I., Mounier, M., Mugneret, F., Bailly, F., Favre, B., Caillot, D., Petrella, T., Flesch, M., Carli, P.-M. . (2010). Twenty-five years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Cote d'Or (Burgundy, France). *Haematologica*, 96(1), pp.55–61. doi:<https://doi.org/10.3324/haematol.2010.026252>.

Medeiros, V. (2022). *Applications of Flow Cytometry in Hematology*. [online] News-Medical.net. Available at: <https://www.news-medical.net/life-sciences/Applications-of-Flow-Cytometry-in-Hematology>. [Accessed 8 Jan. 2023].

Meyerson, H. (2018). Flow Cytometry in Hematology. *Concise Guide to Hematology*, pp.253–275. doi:[https://doi.org/10.1007/978-3-319-97873-4\\_22](https://doi.org/10.1007/978-3-319-97873-4_22).

Miranda-Filho, A., Piñeros, M., Ferlay, J., Soerjomataram, I., Monnereau, A., Bray, F. (2018). Epidemiological patterns of leukaemia in 184 countries: a population-based study. *The Lancet Haematology*, 5(1), pp.e14–e24. doi:[https://doi.org/10.1016/s2352-3026\(17\)30232-6](https://doi.org/10.1016/s2352-3026(17)30232-6).

Mundt, K.A., Dell, L.D., Boffetta, P., Beckett, E.M., Lynch, H.N., Desai, V.J., Lin, C.K., Thompson, W.J. (2021). The importance of evaluating specific myeloid malignancies in epidemiological studies of environmental carcinogens. *BMC cancer*, [online] 21(1), p.227. doi:<https://doi.org/10.1186/s12885-021-07908-3>.

- Murati, A., Brecqueville, M., Devillier, R., Mozziconacci, M.-J., Gelsi-Boyer, V., Birnbaum, D. (2012). Myeloid malignancies: mutations, models and management. *BMC Cancer*, [online] 12(1). doi:<https://doi.org/10.1186/1471-2407-12-304>.
- Neves, W.B. das, Brito, A.M. de, Vasconcelos, A.P., Melo, F.C. de B.C., Melo, R.A.M. (2019). Incidence and spatial distribution of Chronic Myeloid Leukemia by regions of economic development in the state of Pernambuco, Brazil. *Hematology, Transfusion and Cell Therapy*, 41(3), pp.212–215. doi:<https://doi.org/10.1016/j.htct.2018.08.009>.
- Nguyen, L. dan Zhang, L. (2018). *Chronic eosinophilic leukemia*. [online] Pathologyoutlines.com. Available at: <https://www.pathologyoutlines.com/topic/myeloproliferativecel.html> [Accessed 26 Dec. 2022].
- Onida, F. dan Chalandon, Y. (2018). *Myelodysplastic/Myeloproliferative Neoplasms*. Springer eBooks. Switzerland: Springer Nature. doi:[https://doi.org/10.1007/978-3-030-02278-5\\_75](https://doi.org/10.1007/978-3-030-02278-5_75).
- Osca-Gelis, G., Puig-Vives, M., Saez, M., Gallardo, D., Lloveras, N., Marcos-Gragera, R. (2013). Population-based incidence of myeloid malignancies: fifteen years of epidemiological data in the province of Girona, Spain. *Haematologica*, [online] 98(8), pp.e95–e97. doi:<https://doi.org/10.3324/haematol.2013.084061>.
- Padron, E. dan Gurbuxani, S. (2023). *UpToDate*. [online] Uptodate.com. Available at: <https://www.uptodate.com/contents/chronic-myelomonocytic-leukemia-clinical-features-evaluation-and-diagnosis/> [Accessed 9 Nov. 2023].
- Patnaik, M.M. dan Lasho, T.L. (2020). Evidence-Based Minireview: Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review.

*Hematology*, [online] 2020(1), pp.460–464.  
doi:<https://doi.org/10.1182/hematology.2020000163>.

Pérez, G., Calaf, G., Villalba, M., Prieto, K., Burgos, F. (2019). Frequency of hematologic malignancies in the population of Arica, Chile. *Oncology Letters*. [online] doi:<https://doi.org/10.3892/ol.2019.10858>.

Rajabto, W., Reksodiputro, A.H., Rinaldi, I., Tadjoeidin, H., Priantono, D., Angkasa, Y.K. (2022). Chronic Myeloid Leukemia (CML) at National Referral Hospital in Indonesia. *Siriraj Medical Journal*, [online] 74(8), pp.530–536. doi:<https://doi.org/10.33192/smj.2022.63>.

Riether, C., Schürch, C.M., Ochsenbein, A.F. (2014). Regulation of hematopoietic and leukemic stem cells by the immune system. *Cell Death & Differentiation*, [online] 22(2), pp.187–198. doi:<https://doi.org/10.1038/cdd.2014.89>.

Rindy, L.J. dan Chambers, A.R. (2022). *Bone Marrow Aspiration And Biopsy*. [online] Nih.gov. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK559232/> [Accessed 25 Oct. 2022].

Rodak, B.F. dan Carr, J.H. (2017). *Clinical hematology atlas*. St. Louis (Mo.): Elsevier.

Roman, E., Smith, A., Appleton, S., Crouch, S., Kelly, R., Kinsey, S., Cargo, C., Patmore, R. (2016). Myeloid malignancies in the real-world: Occurrence, progression and survival in the UK's population-based Haematological Malignancy Research Network 2004–15. *Cancer Epidemiology*, 42, pp.186–198. doi:<https://doi.org/10.1016/j.canep.2016.03.011>.

Sant, M., Allemani, C., Tereanu, C., De Angelis, R., Capocaccia, R., Visser, O., Marcos-Gragera, R., Maynadié, M., Simonetti, A., Lutz, J.-M., Berrino, F. (2010). Incidence of hematologic malignancies in Europe by morphologic

subtype: results of the HAEMACARE project. *Blood*, 116(19), pp.3724–3734.  
doi:<https://doi.org/10.1182/blood-2010-05-282632>.

Schiffer, C. dan Atallah, E. (2022). *Overview of the treatment of chronic myeloid leukemia*. [online] Uptodate.com. Available at: <https://www.uptodate.com/contents/overview-of-the-treatment-of-chronic-myeloid-leukemia>[Accessed 5 Dec. 2022].

Schiffer, C. dan Gurbuxani, S. (2022). *Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia*. [online] Uptodate.com. Available at: <https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-acute-myeloid-leukemia> [Accessed 2 Dec. 2022].

Schiffer, C.A. dan Stone, R.M. (2023). *Morphologic Classification and Clinical and Laboratory Correlates*. [online] Nih.gov. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK13452/> [Accessed 6 Nov. 2023].

Sekeres, M. dan Platzbecker, U. (2022). *Overview of the treatment of myelodysplastic syndromes*. [online] Uptodate.com. Available at: <https://www.uptodate.com/contents/overview-of-the-treatment-of-myelodysplastic-syndromes> [Accessed 6 Dec. 2022].

Sekeres, M. dan Lindsley, C. (2023). *UpToDate*. [online] Uptodate.com. Available at: <https://www.uptodate.com/contents/clonal-hematopoiesis-of-indeterminate-potential-chip-and-related-disorders-of-clonal-hematopoiesis> [Accessed 7 Jan. 2023].

Shallis, R.M., Wang, R., Davidoff, A., Ma, X., Podoltsev, N.A., Zeidan, A.M. (2020). Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map. *Blood Reviews*, 42, p.100706.  
doi:<https://doi.org/10.1016/j.blre.2020.100706>.

- Shallis, R.M., Wang, R., Davidoff, A., Ma, X., Zeidan, A.M. (2019). Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. *Blood Reviews*, [online] 36, pp.70–87. doi:<https://doi.org/10.1016/j.blre.2019.04.005>.
- Solans, M., Sanvisens, A., Ameijide, A., Merino, S., Rojas, D., Alemán, A., Banqueri, E., Chico, M., Marcos, A.I., de Castro, V., Gil, L., de Munain, A.L., Puigdemont, M., Sánchez, M.-J., Perucha, J., Ruiz-Armengol, P., Chirlaque, M.D., Guevara, M., Carulla, M., Marcos-Gragera, R. (2022). Incidence of myeloid neoplasms in Spain (2002–2013): a population-based study of the Spanish network of cancer registries. *Scientific Reports*, 12(1). doi:<https://doi.org/10.1038/s41598-021-03734-6>.
- Stock, W. dan Thirman, M. (2022). *UpToDate*. [online] Uptodate.com. Available at: <https://www.uptodate.com/contents/pathogenesis-of-acute-myeloid-leukemia> [Accessed 2 Dec. 2022].
- Tallman, M.S., Kim, H.T., Montesinos, P., Appelbaum, F.R., Javier, Bennett, J.M., Debén, G., Bloomfield, C.D., González, J.D., Feusner, J., González, M., Gallagher, R.E., Miguel, Larson, R.A., Milone, G., Paietta, E., Chelo Rayón, Rowe, J.M., Rivas, C., Schiffer, C.A. (2010). Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group. *Blood*, [online] 116(25), pp.5650–5659. doi:<https://doi.org/10.1182/blood-2010-06-288613>.
- Tallman, M.S., Kim, H.T., Paietta, E., Bennett, J.M., Dewald, G., Cassileth, P.A., Wiernik, P.H., Rowe, J.M. (2004). Acute Monocytic Leukemia (French-American-British classification M5) Does Not Have a Worse Prognosis Than Other Subtypes of Acute Myeloid Leukemia: A Report From the Eastern

Cooperative Oncology Group. *Journal of Clinical Oncology*, 22(7), pp.1276–1286. doi:<https://doi.org/10.1200/jco.2004.08.060>.

Tefferi, A. (2022a). *Clinical manifestations and diagnosis of primary myelofibrosis*. [online] Uptodate.com. Available at: <https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-primary-myelofibrosis> [Accessed 5 Dec. 2022].

Tefferi, A. (2022b). *Diagnosis and clinical manifestations of essential thrombocythemia*. [online] Uptodate.com. Available at: <https://www.uptodate.com/contents/diagnosis-and-clinical-manifestations-of-essential-thrombocythemia> [Accessed 4 Dec. 2022].

Tefferi, A. (2022c). *Management of primary myelofibrosis*. [online] Uptodate.com. Available at: <https://www.uptodate.com/contents/management-of-primary-myelofibrosis> [Accessed 5 Dec. 2022].

Tefferi, A. (2022d). *Overview of the myeloproliferative neoplasms*. [online] Uptodate.com. Available at: <https://www.uptodate.com/contents/overview-of-the-myeloproliferative-neoplasms> [Accessed 5 Dec. 2022].

Tefferi, A. (2022e). *Prognosis and treatment of essential thrombocythemia*. [online] Uptodate.com. Available at: <https://www.uptodate.com/contents/prognosis-and-treatment-of-essential-thrombocythemia/> [Accessed 6 Dec. 2022].

Tefferi, A. (2022f). *Prognosis and treatment of polycythemia vera and secondary polycythemia*. [online] Uptodate.com. Available at: <https://www.uptodate.com/contents/prognosis-and-treatment-of-polycythemia-vera-and-secondary-polycythemia/> [Accessed 4 Dec. 2022].

- Van Etten, R. (2022). *Clinical manifestations and diagnosis of chronic myeloid leukemia*. [online] Uptodate.com. Available at: <https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-myeloid-leukemia/> [Accessed 5 Dec. 2022].
- Varghese, C., Immanuel, T., Ruskova, A., Theakston, E., Kalev-Zylinska, M.L. (2021). The Epidemiology of Myeloproliferative Neoplasms in New Zealand between 2010 and 2017: Insights from the New Zealand Cancer Registry. *Current Oncology*, 28(2), pp.1544–1557. doi:<https://doi.org/10.3390/curroncol28020146>.
- Visser, O., Trama, A., Maynadié, M., Stiller, C., Marcos-Gragera, R., De Angelis, R., Mallone, S., Tereanu, C., Allemani, C., Ricardi, U. Schouten, H.C. (2012). Incidence, survival and prevalence of myeloid malignancies in Europe. *European Journal of Cancer*, 48(17), pp.3257–3266. doi:<https://doi.org/10.1016/j.ejca.2012.05.024>.
- Zoi, K. dan Cross, N.C.P. (2014). Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable. *International Journal of Hematology*, 101(3), pp.229–242. doi:<https://doi.org/10.1007/s12185-014-1670-3>.